Novel Targeted Therapeutics for the Treatment of Multiple Myeloma

Objectives
Examines key scientific and genetic advancements that help us understand myeloma, and discusses critical findings for uncovering more effective and safer myeloma therapies.

Chairs
Jesus F. San Miguel, MD, PhD
Chairman of the Congress
Hospital Universitario de Salamanca

Kenneth C. Anderson, MD
Director, Jerome Lipper Multiple Myeloma Center
Medical Director, Kraft Family Donor Center
Professor of Medicine,
Harvard Medical School
Dana-Farber Cancer Institute

Gareth John Morgan, MD
Professor, Academic Unit of Hematology,
Leeds University

Sponsors
Celgene Corporation
Millennium Pharmaceuticals
Novartis Pharmaceuticals Corporation
Ortho Biotech

Download Abstracts